RCS - Neurimmune - Neurimmune: Promising NI006 Phase1 Results in NEJM

AstraZenecaAnnouncement

22/05/2023 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV1085Aa&default-theme=true

RNS Number : 1085A  Neurimmune  22 May 2023

Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR
Cardiomyopathy Published in the New England Journal of Medicine

Results also presented during late-breaking session at ESC Heart Failure
congress 2023

ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today
that primary results of its Phase 1 proof-of-concept study of NI006, a
recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy,
have been presented in Prague at Heart Failure 2023, a scientific congress of
the European Society of Cardiology (ESC), and published in The New England
Journal of Medicine (DOI: 10.1056/NEJMoa2303765).

 

Amyloid transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic
condition that leads to progressive heart failure and high rate of fatality
within four years from diagnosis.(1,2) Progressive ATTR amyloid depositions
characterize the disease, causing heart failure and death. Despite recent
advances and approved therapies, there remains significant unmet medical need
in treating moderate to severe ATTR-CM, and amyloid depletion may constitute
an important new mechanism to achieve further effectiveness.

NI006 has been designed to target the pathology of ATTR-CM by enabling
depletion of amyloid fibrils in the heart. This Phase 1 study investigated
safety, tolerability, pharmacology, and efficacy at 12 months of NI006
treatment in ascending doses.

Results indicate that the safety profile of NI006 is favorable up to the
highest dose tested. No apparent dose-limiting toxic effects or drug-related
serious adverse reactions were observed. The pharmacokinetic profile was
consistent with that of an IgG antibody, and no antidrug antibodies were
detected. At doses of at least 10 mg per kilogram, cardiac amyloid deposition
(detected by either scintigraphy or cardiac magnetic resonance imaging) was
substantially reduced over a period of 12 months. Reductions were also seen in
levels of biomarkers measuring cardiac stress and cardiomyocyte death,
N-terminal pro-B-type natriuretic peptide and troponin T.

"The depletion of the cardiac ATTR deposits is a rational therapeutic target
to revert disease pathology and restore organ function", said Dr. Pablo
Garcia-Pavia from the Hospital Universitario Puerta de Hierro and CNIC in
Madrid, Spain, and principal investigator of the study. "The results of this
study are very promising and show initial evidence that NI006 acts as a
depleter of cardiac amyloid load with potential to improve cardiac structure,
function and outcomes in ATTR cardiomyopathy."

"ATTR cardiomyopathy is a rare but serious condition that is progressive,
systemic and potentially fatal," said Gianluca Pirozzi, SVP, Head of
Development, Regulatory and Safety, Alexion. "These early results are
encouraging, and we look forward to continuing to evaluate NI006 as a
potential therapeutic option to address the high unmet medical need."

"We thank all patients, their families and investigators, study staff and
collaborators for the participation in the NI006 first-in-human study," said
Prof. Christoph Hock, Chief Medical Officer of Neurimmune. "The NI006 results
warrant further development of this drug candidate with the potential of
reverting disease progression in ATTR amyloidosis."

In 2022, Neurimmune entered into an exclusive global collaboration and license
agreement with Alexion, AstraZeneca's Rare Disease group, for NI006.
Neurimmune will continue to be responsible for completion of the current Phase
1 clinical trial on behalf of Alexion, and Alexion will pay certain trial
costs. Following the Phase 1 trial, Alexion will be responsible for further
clinical development, manufacturing, and commercialization.

1. Lauppe RE, et al. Nationwide prevalence and characteristics of
transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021
Oct;8(2):e001755. doi: 10.1136/openhrt-2021-001755.

2. González-Duarte A, et al. Impact of non-cardiac clinicopathologic
characteristics on survival in transthyretin amyloid polyneuropathy. Neurol
Ther. 2020;9(1):135-149. doi:10.1007/s40120-020-00183-7.

NI006 Published Article in The New England Journal of Medicine:

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Pablo Garcia-Pavia, MD PhD(1); Fabian aus dem Siepen, MD(2); Erwan Donal, MD
PhD(3); Olivier Lairez, MD(4); Peter van der Meer, MD PhD(5); Arnt V. Kristen,
MD(6); Michele F. Mercuri, MD PhD(7); Aubin Michalon, PhD(8); Robert J. A.
Frost, MD PhD(8); Jan Grimm, PhD(8); Roger M. Nitsch, MD(8,9); Christoph Hock,
MD(8,9); Peter C. Kahr, MD(8,10); Thibaud Damy, MD PhD(11).

N Engl J Med 2023; DOI: 10.1056/NEJMoa2303765

The authors' affiliations are as follows: 1) Hospital Universitario Puerta de
Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain, Centro Nacional de
Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Universidad Francisco
de Vitoria (UFV), Pozuelo de Alarcon, Spain 2) University Hospital Heidelberg,
Department of Cardiology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
3) Department of Cardiology, University of Rennes, CHU Rennes, INSERM, LTSI -
UMR 1099, Rennes, France 4) CHU de Toulouse - Hôpital Rangueil, Service de
Cardiologie, 1 Avenue du Pr. Jean Poulhès, 31059 Toulouse, France 5)
Department of Cardiology, University Medical Center Groningen, University of
Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlandsn 6) Cardiovascular
Center Darmstadt, Dieburger Straße 31c, 64287 Darmstadt, Germany 7)
Alexion/AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA 8)
Neurimmune AG, Wagistrasse 18, 8952 Schlieren, Switzerland 9) Institute for
Regenerative Medicine, University of Zurich, Wagistrasse 13, 8952 Schlieren,
Switzerland 10) Center for Molecular Cardiology, University of Zurich,
Wagistrasse 13, 8952 Schlieren, Switzerland 11) Cardiology Department and
French National Reference Centre for Cardiac Amyloidosis, at Hôpitaux
Universitaires Henri Mondor, AP-HP, and IMRB, INSERM, Université Paris Est
Creteil, 94010 Créteil, France.

www.neurimmune.com
(https://stats.newswire.com/x/html?final=aHR0cDovL3d3dy5uZXVyaW1tdW5lLmNvbS8&hit%2Csum=WyIzd3V2ZTMiLCIzd3V2ZTQiLCIzd3V2ZTUiXQ)

Contact Information

Martin Meier-Pfister

Neurimmune Media Team
media@neurimmune.com (mailto:media@neurimmune.com)

SOURCE: Neurimmune

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAMMATMTTTBMJ